The Biotech Rollercoaster Ride: From Lab To Buyout
Caixa Capital Risc's Pablo Cironi On Sanifit's Story
After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.
You may also be interested in...
Spain's biotech start-ups are building an impressive pipeline of drugs but have found financing a challenge, so news of fresh funds for rare diseases group Minoryx has been cheered by the sector.
New Zymeworks CEO Ken Galbraith is laying off at least 25% of the company's staff, including 50% of the senior management team, as the firm looks to advance pivotal trials of its HER2-targeted bispecific antibody zanidatamab.
The Brussels-based company's head of immunology has told Scrip that going into a crowded market against several highly effective biologics across different classes holds no fears for UCB despite some concerns that US prescribers will stick to what they know when it comes to psoriasis therapies.